Blood Podcast

In this insightful conversation, Dr. Taylor Brooks, a clinician and researcher from the Cleveland Clinic, sheds light on bispecific antibodies like epcoritamab and glofitamab in treating aggressive B-cell lymphoma. He discusses their innovative mechanisms and how they address a critical need for patients with relapsed or refractory diffuse large B-cell lymphoma. Key findings from his study reveal promising response rates and survival outcomes, while also highlighting the necessity for further research on TP53 mutations and future treatment strategies.

Join Dr. Sarah C. Rutherford, a lymphoma specialist, Dr. Carla Casulo, a clinician-scientist tackling relapsed follicular lymphoma, and Dr. Aaron Perry, a researcher focused on lymphoma biology. They delve into innovative treatment strategies like bispecific antibodies and CAR T-cell therapies. The conversation explores personalizing therapies based on patient history, the biology behind lymphoma transformation, and how emerging tools like ctDNA can guide treatment choices. Plus, they discuss the potential for cures and the complexities of managing high-risk cases.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this week's episode we’ll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments.Featured ArticlesHigh-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialProfiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsPreclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma

Sung-Yun Pai, a clinician-researcher specializing in Wiskott-Aldrich syndrome, shares vital insights on the latest treatment advancements. He discusses the evolving risk-benefit calculus in therapies due to safer options and longer follow-ups. The conversation highlights challenges like late diagnosis, donor matching, and limited access to gene therapy. Pai stresses the urgency of early referrals to specialized centers and deliberates on the decision-making process between transplant and gene therapy, emphasizing the complexities of achieving full correction.

Explore groundbreaking advances in hemophilia treatment with marstacimab, which effectively reduces bleeding without inhibitors. Discover how matched-donor allogeneic CD19 CAR-T therapy enhances outcomes for adult B-ALL patients, showcasing impressive efficacy after lymphodepleting chemotherapy. Dive into the new CLIPI prognostic index for T-cell cutaneous lymphomas, which could revolutionize patient management by identifying those needing intensified treatment based on key risk factors. Tune in for fascinating insights and developments in hematology!

Explore the intriguing connections between Epstein-Barr virus genomic variants and various human diseases, including hematological malignancies. Discover the timing and impact of somatic GATA1 mutations related to leukemias in individuals with Down syndrome. Dive into new high-risk definitions for multiple myeloma, focusing on crucial cytogenetic abnormalities and their implications for patient outcomes. Additionally, learn how these insights could shape future diagnostics and treatment approaches.

Dr. Mark Litzow, a leading hematology professor from the Mayo Clinic, discusses groundbreaking immunotherapy advancements for Acute Lymphoblastic Leukemia (ALL). He highlights the impressive clinical trial results of treatments like blinatumomab and inotuzumab, boasting high remission rates and improved survival, especially among older patients. The conversation emphasizes the shift towards personalized, less toxic therapies, aiming to enhance patient outcomes and reduce chemotherapy intensity. This innovative approach could revolutionize ALL treatment, offering renewed hope for many.

Discover the promising effects of Azacitidine in treating VEXAS syndrome, showing benefits but also high relapse rates. Learn how advanced genotyping techniques are enhancing blood matching, potentially reducing complications for transfusion patients. Finally, uncover a new therapeutic target related to BAP1 loss in TP53-mutated AML, revealing its unique vulnerabilities and paving the way for innovative treatments using BCL-XL inhibitors. This discussion delves into groundbreaking advancements in the field of blood disorders.